<DOC>
	<DOCNO>NCT02365597</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate ( complete response [ CR ] + partial response [ PR ] ) select dose regimen participant metastatic surgically unresectable urothelial cancer harbor specific FGFR genomic alteration .</brief_summary>
	<brief_title>An Efficacy Safety Study JNJ-42756493 Participants With Urothelial Cancer</brief_title>
	<detailed_description>This multicenter , open-label study ( participant know identity study drug administer ) evaluate efficacy safety JNJ-42756493 participant urothelial cancer . The study comprise 30-days Screening Phase , Treatment Phase comprise 28-day treatment cycle continue disease progression unacceptable toxicity occur , post-treatment Follow-up Phase extend End-of-Treatment Visit participant die , withdraws consent , lose follow-up , end study , whichever come first . The end study define approximately 12 month last participant enrol . Safety monitor throughout study .</detailed_description>
	<criteria>Must histologic demonstration metastatic surgically unresectable urothelial cancer . Minor component variant histology glandular squamous differentiation , evolution aggressive phenotype sarcomatoid micropapillary change acceptable Must measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST , version 1.1 ) baseline Must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Must adequate bone marrow , liver , renal function describe protocol Negative pregnancy test ( urine serum beta human chorionic gonadotropin [ bhCG ] ) Screening woman child bear potential sexually active Must show disease progression accord RECIST , version 1.1 , follow prior chemotherapy metastatic surgically unresectable urothelial cancer . Subjects receive neoadjuvant adjuvant chemotherapy show disease recurrence progression accord RECIST , version 1.1 , within 12 month last dose consider received chemotherapy metastatic setting . These subject refer chemorefractory subject . ( Subjects show disease progression accord RECIST , version 1.1 follow prior treatment antiProgrammed deathligand 1 ( anti PDL1/PD1 ) antibody also eligible ) Received chemotherapy , targeted therapy , definitive radiotherapy , treatment investigational anticancer agent within 2 week ( case nitrosoureas mitomycin C , within 6 week ; case immunotherapy , within 4 week ) first administration study drug . Localized palliative radiation therapy ( include radiation target lesion ) ongoing bisphosphonates denosumab , permit Has persistent phosphate level great upper limit normal ( ULN ) screening ( within 14 day treatment prior Cycle 1 Day 1 ) despite medical management Has history current uncontrolled cardiovascular disease Females pregnant , breastfeeding , plan become pregnant within 3 month last dose study drug male plan father child enrol study within 5 month last dose study drug Has recover reversible toxicity prior anticancer therapy ( except toxicity clinically significant alopecia , skin discoloration , Grade 1 neuropathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Urothelial Cancer</keyword>
	<keyword>JNJ-42756493</keyword>
	<keyword>Tyrosine Kinase Inhibitor</keyword>
</DOC>